Ann: Race to present at IRD Invest virtual, investor conference, page-51

So these are the approximate catalysts we have and their order / timing (my thoughts on order, for grey items we don't really have timings):

• Sheba Trial Paper Published (peer reviewed journal)
• Video updates (mentioned in 19 June transcript)
• Breast Cancer Preclinical "initial results" - late Q3, early Q4 (from 4C)
• FDA IND (no specific timeframe but needed before MRD trial can recruit)
• "Late 2020" - begin Adult R/R AML trial (Israel)
• "End of this year / early next year" - begin MRD trial (USA)
• ASH conference abstract (this conference is early December - https://www.hematology.org/meetings/annual-meeting )

There has also been discussion / speculation here about a possible US-listing and given planned activities in US, this would make sense.

https://hotcopper.com.au/posts/45548571/single